These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 32450253)

  • 41. Targeting a cell state common to triple-negative breast cancers.
    Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
    Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I.
    Shen Y; Yang Y; Wang Z; Lin W; Feng N; Shi M; Liu J; Ma W
    Br J Pharmacol; 2024 Nov; 181(21):4262-4278. PubMed ID: 38982680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bufotalin Suppresses Proliferation and Metastasis of Triple-Negative Breast Cancer Cells by Promoting Apoptosis and Inhibiting the STAT3/EMT Axis.
    Park SJ; Jung HJ
    Molecules; 2023 Sep; 28(19):. PubMed ID: 37836626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
    Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
    Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K.
    Wang R; Jia S; Chen H; Luo K; Zhang L; Song Y; Qing C; Liu D; Zhou H
    Biochem Pharmacol; 2024 Aug; 226():116408. PubMed ID: 38969297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer.
    Xu ST; Xu JH; Zheng ZR; Zhao QQ; Zeng XS; Cheng SX; Liang YH; Hu QF
    Biomed Pharmacother; 2017 Dec; 96():14-21. PubMed ID: 28961506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
    Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer.
    Byun WS; Lim H; Hong J; Bae ES; Lee SB; Kim Y; Lee J; Lee SK; Hong S
    J Med Chem; 2023 Feb; 66(4):3106-3133. PubMed ID: 36786551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity.
    Jeon YJ; Jung SN; Yun J; Lee CW; Choi J; Lee YJ; Han DC; Kwon BM
    Cancer Sci; 2015 Apr; 106(4):413-20. PubMed ID: 25611086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
    Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
    J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.